Supporting Pharmacies as Contraception Access Hubs

January 13, 2026 | Brittany Lee

In recent years, the U.S. contraceptive access landscape has undergone meaningful change: In 2023, FDA approved the first over-the-counter (OTC) daily oral contraceptive (Opill), forging a new path for people to obtain hormonal birth control without visiting a doctor's office. At the same time, ongoing debates over reproductive policy highlight the critical need to expand and diversify access to contraceptive services.

Pharmacies are uniquely positioned to serve as contraception access hubs, as they are closer and more familiar/flexible than traditional health centers for many (i.e., those who face transportation, scheduling, or clinic-based barriers). But to realize that potential, public health agencies and pharmacy stakeholders must navigate policy, reimbursement, outreach efforts, supply challenges, and pharmacy closures/workforce stress, underscoring the need for coordinated public health-pharmacy partnerships.

Evidence Snapshot: Early Impact of OTC Access

Early research offers insight into how OTC access is reshaping contraceptive use. A national survey of 986 individuals who obtained oral contraceptives (prescription or OTC) between 2024 and early 2025 found that:

• 32.5% of participants had used an OTC oral contraceptive.
• Among OTC users, 31.6% were uninsured versus only 3.5% of prescription users.
• Rural residence was more common among OTC users (14.4%) than those using prescription pills (8.4%).

Researchers estimate that OTC oral contraception access is associated with a 31.8% increase in the use of an effective contraceptive method from no contraceptive use, and a 41% increase in OTC oral contraceptive use from a less effective method (e.g., condoms or emergency contraception). These shifts appear to stem largely from convenience and flexibility, as users report that avoiding a provider visit and not having an established provider are reasons for seeking OTC contraception.

These findings highlight an essential takeaway: Individuals who are using OTC contraception are more likely to be uninsured, live in rural areas, and have previously relied on a less effective form of contraception. This underscores the potential for OTC access to close persistent gaps in contraceptive care.

Strain on Pharmacies

Despite the invaluable role pharmacies play in expanding access to contraception, it is important to note that the broader pharmacy ecosystem is under significant stress. Over the past decade, nearly 1 in 3 U.S. retail pharmacies shut their doors. Between 2009 and 2015, roughly 1 in 8 pharmacies closed, many independent and low-income area establishments. In rural areas from 2003 to 2021, the total number of retail pharmacies declined by nearly 10%, while independent pharmacies shrank by over 16%. These closures contribute to “pharmacy deserts,” areas where residents lack convenient access to pharmacy services. National estimates show that 15.8 million people (4.7% of the U.S. population) live in pharmacy deserts, often overlapping with low-income, less-educated groups with greater chronic health needs.

Meanwhile, pharmacists are managing increasing workloads, staffing shortages, and expanding responsibilities. These pressures can limit pharmacists’/pharmacy technicians’ time to answer consumer questions, ensure consistent product stocking, or manage new OTC product logistics. Addressing workforce capacity with sustainable staffing and clear operational guidance is vital to realizing the promise of expanded OTC contraceptive access.

Policy and Program Levers for Public Health Agencies

Coverage and Reimbursement

Jurisdictions may seek clarification on health plans providing coverage for OTC contraceptives and under what conditions (e.g., if a prescription is required, any quantity limits, etc.). To mitigate cost barriers, states may seek policy that requires insurers to cover OTC contraceptives without cost sharing and issue clear guidance for pharmacies on billing/claims submission. As of November 2025, 11 states have enacted legislation related to OTC contraceptive coverage in either state-regulated plans or state Medicaid plans. For example, in North Carolina, Medicaid beneficiaries can obtain Opill at retail pharmacies without a prescription or cost sharing, and pharmacies are able to bill Medicaid for it.

Retail Access and Distribution

Working with chain and independent pharmacies can help ensure that OTC contraceptives are stocked, easy to access (i.e., not locked away), and priced competitively. States might also explore alternative distribution models, such as wellness vending machines, mobile units, or peer distribution in underserved settings. Connecticut recently launched a program allowing licensed vending machines to dispense emergency contraception and other OTC reproductive health products. The initiative aims to increase convenient, confidential access to contraception outside of traditional pharmacy hours, demonstrating how state agencies can collaborate with regulatory partners to modernize retail access and reduce logistical barriers to care.

Public Awareness and Education

Campaigns are one way to raise awareness for OTC contraceptive options, access points, and costs. Partnering with pharmacies to co-brand signage, promote point-of-sale reminders, and provide staff training can bolster visibility of products. Washington state has issued client-facing and pharmacy-facing FAQs and bulletins through Apple Health, the state’s Medicaid program, explaining that OTC contraception is covered without a prescription and at no cost to the patient.

Access Considerations and Challenges

Cost remains a significant hurdle. Currently, many insurers and Medicaid programs are not explicitly or uniformly required to cover OTC contraceptives, especially when purchased without a prescription. This leads to many users paying out of pocket, and recent research indicates that the current price point (i.e., with a three-month Opill supply retailing at about $50) could contribute to low uptake: Fewer than 1 in 5 women are willing or able to pay more than $20 per month for an OTC oral contraceptive, and 11% of reproductive-aged women in one national survey said they would not be willing or able to pay anything.

The growing number of pharmacy deserts also threatens OTC contraception access, as closures may disproportionately affect rural and low-income communities, undermining those who could benefit the most. Additionally, stocking practices within pharmacies may unintentionally create barriers. When contraceptives 1) are in locked cases requiring staff assistance, 2) lack lower cost generic options (i.e., condoms and OTC emergency contraception), or 3) are understocked, their accessibility and ease of use significantly decrease.

Misconceptions among consumers and providers regarding safety, side effects, or eligibility may also limit uptake. For example, focus groups with Black and Latinx young people showed many were unaware of OTC oral contraceptive options and held misconceptions about their safety even after FDA approval. Research shows knowledge gaps and other objections to providing product access (e.g., customers being told there is an age restriction) are increasing barriers to emergency contraception. These misconceptions could also affect how Opill is sold in retail settings.

Moving Forward

Public health leaders can support pharmacies’ role as contraceptive access hubs by:

• Undertaking a comprehensive state assessment of pharmacy locations (including recent closures), insurance coverage across pharmacies, and OTC product availability.
• Engage insurance commissioners and regulators to discuss OTC contraceptive coverage without cost sharing and prescription requirements, and opportunities to promote access and encourage compliance.
• Convene pharmacy leadership, retail chain executives, and associations to define OTC contraception standards and best practices for policy implementation, stocking, and consumer experience.
• Launch coordinated outreach to pharmacies, communities, and individuals to raise awareness of OTC contraceptive availability and navigate barriers to access.